Related Experiment Video
Updated: Jun 13, 2026
Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles
Published on: June 28, 2021
A Novel Acidic Polysaccharide from Inonotus obliquus (IOP-1) Suppresses Growth and Induces Apoptosis in Non-Small
Jiaqi Zhao1, Wei Xie2, Xinze Liu1
1Changchun University of Chinese Medicine Jilin Ginseng Academy Changchun China.
Introduction:
The aim of this study was to investigate the antitumor effect of IOP-1 on non-small cell lung cancer (NSCLC) and its mechanism Materials: We isolated and purified an acidic polysaccharide component from Inonotus obliquus, identified its specific functional groups and monosaccharide composition, and named it IOP-1. We studied the mechanism of IOP-1 on non-small cell lung cancer through a series of in vitro experiments and measured relevant indicators in in vivo experiments. Through the results of both in vivo and in vitro experiments, we explored the mechanism of action and antitumor effects of IOP-1 in non-small cell lung cancer.
Results:
We isolated and purified an acidic polysaccharide component from Inonotus obliquus, identified its specific functional groups and monosaccharide composition, and named it IOP-1. Studies found that IOP-1 can inhibit the proliferation and migration of NCI-H460 cells and induce their apoptosis. When IOP-1 was applied to NCI-H460 cells, the expression of Bax, Bcl-2, MMP-9, and Parp-1 decreased, while the expression of P53 and Cyto-c increased. Experiments in mice showed that IOP-1 can effectively inhibit tumor growth, increase spleen weight, and reduce blood perfusion in mice. Compared with the model group, dietary conditions improved.
Discussion:
IOP-1 has significant antitumor activity against NCI-H460 cells, inhibiting the growth and migration of non-small cell lung cancer by regulating apoptosis and migration-related pathways.
Conclusions:
As a new drug, IOP-1 provides a new method for the clinical treatment of non-small cell lung cancer.
Insights
An acidic polysaccharide, IOP-1, derived from Inonotus obliquus, demonstrates significant antitumor effects against non-small cell lung cancer (NSCLC). IOP-1 inhibits cancer cell proliferation and migration, offering a promising new therapeutic avenue for NSCLC treatment.
Area of Science:
- Biochemistry
- Pharmacology
- Oncology
Background:
- Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality worldwide.
- Investigating novel therapeutic agents for NSCLC is crucial for improving patient outcomes.
- The potential of natural compounds like polysaccharides from Inonotus obliquus warrants exploration for anticancer properties.
Purpose of the Study:
- To investigate the antitumor effects of an acidic polysaccharide, designated IOP-1, isolated from Inonotus obliquus.
- To elucidate the underlying mechanisms of IOP-1's action against NSCLC cells.
- To evaluate the therapeutic potential of IOP-1 in preclinical models of NSCLC.
Main Methods:
- Isolation and purification of acidic polysaccharide IOP-1 from Inonotus obliquus.
- Characterization of IOP-1's functional groups and monosaccharide composition.
- In vitro studies using NCI-H460 NSCLC cells to assess proliferation, migration, and apoptosis.
- In vivo experiments in mice to evaluate tumor growth inhibition and relevant physiological parameters.
Main Results:
- IOP-1 significantly inhibited proliferation and migration of NCI-H460 cells while inducing apoptosis.
- IOP-1 treatment altered the expression of key apoptosis-related proteins (Bax, Bcl-2, P53, Cyto-c) and migration-related proteins (MMP-9, Parp-1).
- In vivo studies demonstrated that IOP-1 effectively inhibited tumor growth, increased spleen weight, and reduced tumor blood perfusion in mice.
Conclusions:
- IOP-1 exhibits potent antitumor activity against NSCLC by modulating apoptosis and migration pathways.
- The findings suggest that IOP-1 is a promising candidate for the development of novel NSCLC therapeutics.
- IOP-1 represents a new therapeutic strategy for the clinical management of non-small cell lung cancer.
Related Concept Videos
01:31The Intrinsic Apoptotic Pathway
02:34Inhibition of Cdk Activity
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...